Efficacy of Omalizumab in Indolent Systemic Mastocytosis
Joint Authors
Hicks, Lisa K.
Slapnicar, Calum
Trinkaus, Martina
Vadas, Peter
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-16
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background.
Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs.
Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficacy of SM is limited.
Methods.
A retrospective analysis of 6 patients diagnosed with indolent SM treated with omalizumab at St.
Michael’s Hospital between 2009 and 2018 is described.
Reported frequency of anaphylaxis, baseline and follow-up tryptase levels, and SM-related symptoms were captured to measure the control of the disease.
Results.
Of the 5 patients who had experienced unprovoked anaphylaxis prior to treatment with omalizumab, 3 had no further episodes of anaphylaxis following initiation of omalizumab, while the remaining 2 patients had milder multisystem reactions.
Significant improvement in cutaneous symptoms was also observed.
Conclusion.
These data suggest that omalizumab provides benefit to patients with SM who remain highly symptomatic in spite of treatment with conventional therapies.
American Psychological Association (APA)
Slapnicar, Calum& Trinkaus, Martina& Hicks, Lisa K.& Vadas, Peter. 2019. Efficacy of Omalizumab in Indolent Systemic Mastocytosis. Case Reports in Hematology،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1136528
Modern Language Association (MLA)
Slapnicar, Calum…[et al.]. Efficacy of Omalizumab in Indolent Systemic Mastocytosis. Case Reports in Hematology No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1136528
American Medical Association (AMA)
Slapnicar, Calum& Trinkaus, Martina& Hicks, Lisa K.& Vadas, Peter. Efficacy of Omalizumab in Indolent Systemic Mastocytosis. Case Reports in Hematology. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1136528
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1136528